UK's CMA Goes After Advanz, Morningside And Alliance On Nitrofurantoin
Executive Summary
The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.
You may also be interested in...
UK’s CMA Issues £35m In Fines Over Prochlorperazine
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.
UK’s CMA Issues £35m In Fines Over Prochlorperazine
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.
UK’s CMA Puts Investigations On Hold
Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.